z-logo
Premium
Novel dual‐responsive semi‐interpenetrating polymer network hydrogels for controlled release of anticancer drugs
Author(s) -
Dadfar Seyed Mohammad Reza,
Pourmahdian Saeed,
Tehranchi Mohammad Mehdi,
Dadfar Seyed Mohammadali
Publication year - 2019
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.36741
Subject(s) - self healing hydrogels , doxorubicin hydrochloride , materials science , interpenetrating polymer network , polymer , drug delivery , radical polymerization , polymerization , nanogel , controlled release , doxorubicin , nuclear chemistry , chemical engineering , polymer chemistry , nanotechnology , chemistry , composite material , medicine , surgery , engineering , chemotherapy
Novel dual‐responsive hydrogels of semi‐interpenetrating polymer networks (semi‐IPNs) based on temperature‐sensitive N ‐isopropylacrylamide (NIPAA) and pH‐sensitive N ‐ethylmaleamic acid (NEMA) monomers and sodium alginate polymer were synthesized using free‐radical polymerization in the presence of N , N ′‐methylenebisacrylamide as a crosslinker. Stimuli‐responsive properties of the semi‐IPN hydrogels showed remarkable sensitivity to both temperature and pH without limitation in NEMA content. Doxorubicin hydrochloride (DOX) as a model drug was efficiently loaded into the hydrogels and the release profiles of drug from them were investigated. The results of in vitro studies showed a quick DOX release in the conditions simulating tumor environment (phosphate‐buffered saline [PBS], pH 6.5, 37°C) or endosomes/lysosomes (PBS, pH 5.5, 37°C) compared to simulated human physiological conditions (PBS, pH 7.4, 37°C). In conclusion, the novel poly(NIPAA‐co‐NEMA) semi‐IPN hydrogels could be a promising candidate for targeted and controlled release of anticancer drugs in drug delivery system.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here